(UTMD) Utah Medical Products - Overview
Stock: Fetal, Monitoring, Delivery, Catheters, Gynecology
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.10% |
| Yield on Cost 5y | 1.48% |
| Yield CAGR 5y | -19.07% |
| Payout Consistency | 63.3% |
| Payout Ratio | 34.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 23.0% |
| Relative Tail Risk | -10.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.15 |
| Alpha | -3.63 |
| Character TTM | |
|---|---|
| Beta | 0.387 |
| Beta Downside | 0.253 |
| Drawdowns 3y | |
|---|---|
| Max DD | 46.46% |
| CAGR/Max DD | -0.22 |
Description: UTMD Utah Medical Products January 25, 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) designs and manufactures a broad portfolio of disposable and reusable medical devices for labor-and-delivery, neonatal intensive care, and women’s health applications, ranging from fetal monitoring accessories and vacuum-assisted delivery systems to umbilical catheters, peritoneal dialysis sets, and electrosurgical tools.
In its most recent 10-K (FY 2023), UTMD generated **$140.2 million** in revenue, up **12 % YoY**, driven primarily by higher sales of its DELTRAN pressure-monitoring line and expanding NICU product adoption. Gross margin remained solid at **~55 %**, while R&D expenses represented **≈8 %** of revenue, reflecting continued investment in new catheter and electrosurgical technologies.
The company’s market capitalization sits near **$340 million**, with a cash-on-hand position of **$45 million** and a debt-to-equity ratio of **0.2**, indicating a relatively low leverage profile for a medical-device firm. Recent earnings calls highlighted a **3-year CAGR of ~9 %** in the broader health-care supplies sector, underpinned by rising NICU admissions and a sustained increase in labor-and-delivery volumes as the U.S. birth rate stabilizes.
Key macro drivers include an aging population that fuels demand for minimally invasive gynecologic procedures, and ongoing hospital cost-containment pressures that favor disposable, single-use devices-segments where UTMD’s product mix is well-aligned.
For a deeper quantitative assessment, a quick look at ValueRay’s metrics can help you gauge the stock’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 11.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -2.66 > 1.0 |
| NWC/Revenue: 247.0% < 20% (prev 226.3%; Δ 20.68% < -1%) |
| CFO/TA 0.12 > 3% & CFO 14.2m > Net Income 11.3m |
| Net Debt (-85.5m) to EBITDA (16.7m): -5.13 < 3 |
| Current Ratio: 37.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.20m) vs 12m ago -5.61% < -2% |
| Gross Margin: 52.92% > 18% (prev 0.56%; Δ 5236 % > 0.5%) |
| Asset Turnover: 31.43% > 50% (prev 33.38%; Δ -1.95% > 0%) |
| Interest Coverage Ratio: -35.17 > 6 (EBITDA TTM 16.7m / Interest Expense TTM -390.0k) |
Altman Z'' 10.00
| A: 0.78 (Total Current Assets 97.7m - Total Current Liabilities 2.60m) / Total Assets 122.5m |
| B: 1.04 (Retained Earnings 128.0m / Total Assets 122.5m) |
| C: 0.11 (EBIT TTM 13.7m / Avg Total Assets 122.5m) |
| D: 36.43 (Book Value of Equity 119.3m / Total Liabilities 3.27m) |
| Altman-Z'' Score: 47.50 = AAA |
Beneish M -3.16
| DSRI: 0.91 (Receivables 3.52m/4.09m, Revenue 38.5m/40.9m) |
| GMI: 1.07 (GM 52.92% / 56.50%) |
| AQI: 0.91 (AQ_t 0.12 / AQ_t-1 0.13) |
| SGI: 0.94 (Revenue 38.5m / 40.9m) |
| TATA: -0.02 (NI 11.3m - CFO 14.2m) / TA 122.5m) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of UTMD shares?
Over the past week, the price has changed by +0.95%, over one month by +7.69%, over three months by +7.07% and over the past year by +5.11%.
Is UTMD a buy, sell or hold?
What are the forecasts/targets for the UTMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 62.7 | 1.7% |
UTMD Fundamental Data Overview January 31, 2026
P/S = 5.1156
P/B = 1.6534
Revenue TTM = 38.5m USD
EBIT TTM = 13.7m USD
EBITDA TTM = 16.7m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 241.0k USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -85.5m USD (calculated as Total Debt 241.0k - CCE 85.8m)
Enterprise Value = 112.1m USD (197.6m + Debt 241.0k - CCE 85.8m)
Interest Coverage Ratio = -35.17 (Ebit TTM 13.7m / Interest Expense TTM -390.0k)
EV/FCF = 8.08x (Enterprise Value 112.1m / FCF TTM 13.9m)
FCF Yield = 12.38% (FCF TTM 13.9m / Enterprise Value 112.1m)
FCF Margin = 36.04% (FCF TTM 13.9m / Revenue TTM 38.5m)
Net Margin = 29.30% (Net Income TTM 11.3m / Revenue TTM 38.5m)
Gross Margin = 52.92% ((Revenue TTM 38.5m - Cost of Revenue TTM 18.1m) / Revenue TTM)
Gross Margin QoQ = 52.31% (prev 51.57%)
Tobins Q-Ratio = 0.91 (Enterprise Value 112.1m / Total Assets 122.5m)
Interest Expense / Debt = 732.0% (Interest Expense 1.76m / Debt 241.0k)
Taxrate = 17.42% (541.0k / 3.11m)
NOPAT = 11.3m (EBIT 13.7m * (1 - 17.42%))
Current Ratio = 37.62 (Total Current Assets 97.7m / Total Current Liabilities 2.60m)
Debt / Equity = 0.00 (Debt 241.0k / totalStockholderEquity, last quarter 119.3m)
Debt / EBITDA = -5.13 (Net Debt -85.5m / EBITDA 16.7m)
Debt / FCF = -6.16 (Net Debt -85.5m / FCF TTM 13.9m)
Total Stockholder Equity = 118.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.21% (Net Income 11.3m / Total Assets 122.5m)
RoE = 9.56% (Net Income TTM 11.3m / Total Stockholder Equity 118.0m)
RoCE = 11.44% (EBIT 13.7m / Capital Employed (Total Assets 122.5m - Current Liab 2.60m))
RoIC = 9.63% (NOPAT 11.3m / Invested Capital 117.6m)
WACC = 7.33% (E(197.6m)/V(197.9m) * Re(7.34%) + (debt cost/tax rate unavailable))
Discount Rate = 7.34% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -6.13%
[DCF Debug] Terminal Value 78.76% ; FCFF base≈15.2m ; Y1≈13.4m ; Y5≈10.9m
Fair Price DCF = 97.33 (EV 226.3m - Net Debt -85.5m = Equity 311.8m / Shares 3.20m; r=7.33% [WACC]; 5y FCF grow -14.79% → 2.90% )
EPS Correlation: -69.76 | EPS CAGR: -8.18% | SUE: N/A | # QB: 0
Revenue Correlation: -91.20 | Revenue CAGR: -7.92% | SUE: N/A | # QB: 0